G C A T
T A C G
G C A T

genes

Review

Targeting MicroRNAs in Cancer Gene Therapy
Weidan Ji † , Bin Sun † and Changqing Su *
Department of Molecular Oncology, Eastern Hepatobiliary Surgery Hospital & National Center of Liver Cancer,
Second Military Medical University, Shanghai 200433, China; jiweidan326@163.com (W.J.);
sunbin05301984@aliyun.com (B.S.)
* Correspondence: suchangqing@gmail.com; Tel.: +86-21-8187-5351
† These authors contributed equally to this work.
Academic Editor: Michael Barry
Received: 18 November 2016; Accepted: 30 December 2016; Published: 9 January 2017

Abstract: MicroRNAs (miRNAs) are a kind of conserved small non-coding RNAs that participate
in regulating gene expression by targeting multiple molecules. Early studies have shown that the
expression of miRNAs changes significantly in different tumor tissues and cancer cell lines. It is
well acknowledged that such variation is involved in almost all biological processes, including
cell proliferation, mobility, survival and differentiation. Increasing experimental data indicate that
miRNA dysregulation is a biomarker of several pathological conditions including cancer, and that
miRNA can exert a causal role, as oncogenes or tumor suppressor genes, in different steps of the
tumorigenic process. Anticancer therapies based on miRNAs are currently being developed with
a goal to improve outcomes of cancer treatment. In our present study, we review the function of
miRNAs in tumorigenesis and development, and discuss the latest clinical applications and strategies
of therapy targeting miRNAs in cancer.
Keywords: cancer; microRNA; gene therapy; oncogene; tumor suppressor gene

1. Introduction
MicroRNAs (miRNAs)—a group of small endogenous non-coding functional RNAs—are
approximately 18–22 nucleotides in length and widespread in plants and animals [1]. Studies have
demonstrated the significance of miRNA biosynthesis and regulatory function in maintaining cellular
homeostasis [2]. miRNAs are transcribed by RNA polymerase II, from initial processing to final
maturing [3–5]. They are then incorporated into the RNA-induced silencing complex (RISC) together
with Argonaute to silence target messenger RNA (mRNAs) usually through imperfect complementary
base pairing to the 30 -untranslated region [6,7]. A single mRNA may possibly be targeted by multiple
different miRNAs with variable efficiencies. Conversely, a single miRNA may target more than
one mRNA. Through their binding to target mRNA sequences, miRNAs have various biological
functions. They have an ability to inhibit or promote the expression of many related genes, which can
affect several cell-signaling pathways essential to tumor development and progression, such as cell
proliferation, differentiation, mobility and apoptosis [8,9]. A global reduction or increase of mature
miRNAs is observed in cancer and involved in cancer biological behaviors, which has made miRNAs
attractive candidates for cancer therapy.
2. miRNAs and Cancer
Carcinogenesis is a multistep process. Normal cells experience genetic changes to promote cells
through pre-malignant initiation into malignant status. Microarray expression data demonstrated that
the aberrant miRNA expression is a common event in cancer [10–12]. Importantly, studies featuring
miRNA over-expression or ablation on mouse models demonstrated the correlations between miRNAs

Genes 2017, 8, 21; doi:10.3390/genes8010021

www.mdpi.com/journal/genes

Genes 2017, 8, 21

2 of 15

and cancer development [13,14]. Increasing evidence suggests that miRNAs might play a large and
unanticipated role in the occurrence and development of human cancer. A study on a genome-wide
basis by mapping 186 miRNAs found that miRNAs were frequently located at fragile sites, minimal
regions of heterozygous loss or amplification, or common break-point regions in human cancers [15].
Besides the structural and genetic alterations, the epigenetic silencing of miRNAs genes by DNA
promoter hypermethylation or histone hypoacetylation has been clarified in some solid tumors and
hematological malignancies [16–18].
With the development of genomics, miRNA expression profiles between tumor tissues and
normal tissues could be rapidly established through high-throughput technologies such as gene chips,
real-time PCR, etc. Dysregulation of miRNA expression has been confirmed in most tumors [19,20].
The up-regulated miRNAs in tumor cells are commonly considered to be oncogenic miRNAs
(oncomiRs), which can silence the tumor suppressor genes. miR-21 is a very widely studied oncomiR
and has been reported at high expression levels in glioblastoma [21], pancreatic cancer [22], breast
cancer [23] and colon cancer [24]. It exerts an antiapoptotic effect by targeting the tumor suppressors
such as phosphatase and tensin homolog (PTEN) and programmed cell death 4 (PDCD4) [25,26].
Conversely, some miRNAs, which are often down-regulated in most cancers, can inhibit tumor
progression and are termed tumor suppressor miRNAs. These miRNAs target mRNAs of some
oncogenes and inhibit the carcinogenic effect by repressing the translation of oncogenic mRNAs [27].
For example, miRNAs are frequently lost in cancer, such as miR-15/miR-16 in chronic lymphocytic
leukemia [20]. The miR-15a/miR-16-1 cluster can directly interact with bcl-2 mRNA and inhibit its
protein translation, which induces apoptosis of leukemic cells. Loss of miR-15a/miR-16-1 results in an
inhibition of leukemia cell apoptosis [28]. Tumorigenesis and development are usually associated with
the down-regulation of tumor suppressive miRNAs and the up-regulation of oncomiRs.
Over-expression or down-regulation of some specific miRNAs in different tumors makes them to
be potential therapeutic targets. The circulating miRNAs released from their producer cells are novel
non-invasive biomarkers in cancers. Several studies detected the circulating miRNAs in cancer patients
and discussed their potential relationship to the primary tumors [29]. The circulating miRNAs could be
detected in body fluids (blood, urine, tears, saliva, seminal fluid, cerebrospinal fluid, and extracellular
fluid) in a fairly stable form and are considered to be valuable in diagnosis and in evaluating prognosis
and monitoring treatment response [30,31]. It was reported that the levels of tumor-suppressor
miRNAs increased in circulation and are involved in immune responses [32]. Extracellular miRNAs
released from normal or tumor cells may function as mediators of paracrine or endocrine signaling
pathways among different kinds of tumor cells [33–35]. In conclusion, miRNAs may be used for
clinical applications in cancer management, not only in tumor diagnosis, but in evaluating malignant
potential or therapeutic efficiency, and in monitoring tumor recurrence and progression.
3. Strategies of miRNA-Based Cancer Gene Therapy
Intracellular miRNAs bind to the mRNAs of target genes with complementary sequences to induce
mRNA degradation or inhibit mRNA translation, thereby exerting their role as post-transcriptional
regulators of target genes [36]. Abnormal expression of miRNAs is closely related to cancers. For the
purpose of correcting abnormal miRNA expression, miRNA-based gene therapy is becoming a new
target strategy for malignant tumors [37]. During recent years, the strategies of miRNA-based tumor
treatment are mainly as follows: (1) To inhibit proliferation or induce apoptosis of tumor cells by
importing exogenous miRNAs, which are tumor suppressor miRNAs and down-regulated in tumor
tissues. For example, the chemically synthesized miRNA mimics are used to imitate endogenous
mature double-stranded miRNA with the aim to restore/enhance endogenous miRNA function [38,39].
Construction of viral vectors (adenoviral, lentiviral and retroviral vectors), which express specific
miRNAs, could enhance the function of miRNAs in tumor cells; (2) To inhibit the function of
miRNAs, which are oncogenic miRNAs and over-expressed in tumors, by applying the antisense
oligonucleotides (ASOs) strategy, including anti-miRNA oligonucleotides (AMOs), miRNA antagomirs,

Genes 2017, 8, 21

3 of 15

locked-nucleic-acids antisense oligonucleotides (LNAs), miRNA sponges, multiple-target anti-miRNA
antisense oligodeoxyribonucleotides (MTg-AMOs), miRNA-masking and nanoparticles [40–43]. LNAs
and AMOs are the main types of ASOs that could inhibit miRNA target genes based on complementary
base pairing. Antagomir—a small synthetic RNA and complementary to the specific miRNA
target—is modified to make it more resistant to degradation [44,45]. Recent studies reported a tumor
treatment strategy that simultaneously disturbs the function of multiple oncogenic miRNAs (miRNA
sponges). This strategy used a tumor-selective replicating viral vector to mediate the expression of
an artificially designed interfering long non-coding RNA (lncRNA), which comprises the binding
sites of multiple oncogenic miRNAs and thus neutralizes oncogenic miRNAs in cancer cells, fully
protecting the function of tumor suppressor genes and exhibiting an effective anti-tumor effect
in vitro and in vivo [46,47]; (3) Artificial miRNA, designed to target single or multiple malignant
tumor phenotype-related genes, provides a new therapeutic strategy for cancers [48,49]. The strategy
used natural miRNA precursor (pre-miRNA) structures, and specifically interfered with target gene
expression by replacing core sequences of pre-miRNA with complementary sequences of target genes.
Artificial miRNAs have a stronger silencing effect on target genes compared with short hairpin RNAs
(shRNAs); they are regulated by polymerase II promoter to achieve tissue-specific or regulatory
expression. The most important feature is its high safety, low toxicity, less effect with cell endogenous
RNA interfering (RNAi) and off-target [50–53].
Until now, some studies of tumor gene therapy targeting miRNA have obtained anti-tumor effects
in vivo and in vitro, and laid a foundation for the safe and effective application for tumor patients
(Table 1).

Genes 2017, 8, 21

4 of 15

Table 1. MicroRNAs (miRNAs) involved in cancers.
MicroRNA

Function

Targets

Experimental Data

Therapeutic Strategy

Reference

miR-145

Tumor suppressor

ROCK1, MMP11, Rab27a,
FSCN-1, LASP1, MTDH, SENP1,
E2F3, MUC13, c-Myc

In vitro experiments in nasopharyngeal, bladder, cervical, lung, liver, breast, gastric,
prostate cancer cell lines
In vivo experiments in prostate, pancreatic, bladder cancers and multiple myeloma

Mimics
Vector-based (viral)

[54–68]

miR-34a

Tumor suppressor

CDK6, SIRT1, E2F3, c-Met,
Notch, c-Myc, Fra-1, TPD52,
c-SRC, Bcl-2, MYCN

In vitro experiments in neuroblastoma, glioblastoma and liver, prostate, colon, breast
cancer cell lines
In vivo experiments in multiple myeloma, glioma and prostate xenografts in mice

Mimics
Vector-based (viral)

[69–80]

miR-29b

Tumor suppressor

DNMT3A/3B, CDK6, MCL-1,
TCL-1, Bcl-2, KDM2A, MMP2,
TNFAIP3/A20, BCL2L2

In vitro experiments in glioblastomas, acute myelocytic leukemia (AML), liver, lung,
gastric cancer cells
In vivo experiments in AML, liver and lung cancers

Mimics
Vector-based (viral)

[81–90]

Let-7a

Tumor suppressor

K-RAS, N-RAS, CDK6, CDC25A,
HMGA2, MYC, RTKN, E2F2

In vitro experiments in lung, gastric, breast and colon cancer cells
In vivo experiments in breast and lung cancers

Mimics
Vector-based (viral)

[91–101]

miR-340

Tumor suppressor

ROCK1, MYO10, MET, CDH1,
NF-x03BA/B1, JAK1, EZH2

In vitro experiments in liver, glioma, ovarian, breast, lung cancer cells
In vivo experiments in liver cancer

Mimics
Vector-based (viral)

[102–108]

miR495

Tumor suppressor

MYB, Bim-1, MTA3,
JAM-A, PRL-3

In vitro experiments in glioma, AML, lung, breast, gastric, prostate cancer cells
In vivo experiments in endometrial, breast, prostate cancers and leukemia

Mimics
Vector-based (viral)

[109–117]

miR155

Oncogene

SHIP-1, C/EBPβ, S0CS1, SOCS6,
FBXW7, ZDHHC2

In vitro experiments in liver cancer and myeloid cells
In vivo experiments in pre-B lymphoma/Leukemia and liver cancer

Antisense oligos
miR-MASK
Sponges

[118–126]

miR-21

Oncogene

PDCD4, PTEN, TPM1, FOXO1,
Rho-B, BTG-2, Cdc25A

In vitro experiments in multiple myeloma, glioblastoma, lung, colon, breast and liver
cancer cells
In vivo experiments in multiple myeloma

Antisense oligos
miR-MASK
Sponges or LNA

[127–133]

Genes 2017, 8, 21

5 of 15

4. Therapy Targeting miRNAs in Human Cancers
The potential of miRNAs as treatment targets in cancers has been explored by many studies.
The therapeutics strategies either introducing tumor suppressor miRNAs or blocking oncogenic
miRNAs have developed rapidly in recent years.
4.1. Breast Cancer
Breast cancer is a malignant disease threatening the health of women worldwide due to its
high capability of recurrence and metastasis. A growing number of studies have demonstrated that
miRNAs play critical roles in the development of breast cancer. Romero-Cordoba et al. found that
113 miRNAs showed higher expression and 17 miRNAs were down-regulated in breast tumors
compared to the normal adjacent tissue [134]. Furthermore, differential expression of miRNAs
has been tightly linked with a high incidence and mortality of breast cancer. It has been well
documented that miR-892b expression is obviously down-regulated in human breast cancer specimens.
Over-expression of miR-892b by its mimics in breast cancer cells significantly decreased tumor growth,
metastatic capacity, and induced angiogenesis in vitro and in vivo, which was mediated by attenuating
nuclear transcription factor kappa B (NF-κB) signaling pathway [135]. miR-155 is usually considered
to be an oncogenic miRNA in breast cancer. miR-155 antisense oligonucleotide (miR-155 ASO)
was synthetized and transfected into MDA-MB-157 cells, the cell proliferation was remarkably
inhibited and cell apoptosis was increased [118]. In addition, the use of artificial miRNAs (amiRNA)
provides a new strategy for breast cancer therapy. A novel amiRNA, miR p-27-5p, which targets
the 30 -untranslated region (30 -UTR) of cyclin-dependent kinase 4 (CDK4) mRNA, was introduced
into breast cancer cells. This study revealed that cell proliferation was inhibited and cell cycle was
arrested through down-regulation of CDK4 expression and suppression of retinoblastoma protein (RB1)
phosphorylation [136]. Liang et al. constructed an amiRNA by inserting a double-stranded miRNA
gene against a C-X-C motif chemokine receptor 4 (CXCR4) into a miR-155-based RNAi expression
vector, which exhibited a reduced expression level of CXCR4 and a suppressed migration and invasion
in breast cancer cells [137].
4.2. Hepatocellular Carcinoma
Similar to other malignancies, the pathogenesis of hepatocellular carcinoma (HCC) is a complex
with contribution of genetic and epigenetic changes. MiRNAs have been implicated in HCC
metastasis. Zhou et al. found that miR-625 was consistently down-regulated in HCC specimens
and its re-expression in HCC cells effectively suppressed cell migration and invasiveness by regulating
the insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)/ PTEN pathway [138]. Gougelet
and his colleagues used a mouse model in which β-catenin signaling was over-activated exclusively
in the liver. They found that treatment with an LNA-derived inhibitor of miR-34a remarkably
halved progression rates for tumors [69]. As a variety of delivery systems had been applied in
HCC gene therapy, liposome-based carrier system was reported to be a potential approach. A new
transferrin-targeted delivery system of negatively charged liposomes encapsulating anti-miR-221
was developed and effectively delivered anti-miR-221 to HepG2 cells, which significantly reduced
the level of miR-221 [139]. Since previous studies indicated that amiRNA might be a promising
therapeutic modality in gene therapy, Huang et al. constructed amiRNAs targeting firefly luciferase
with the precursor frameworks of six highly abundant miRNAs in HCC. The results showed that
the miR-221 precursor-based amiRNA exhibited a greatest knockdown effect on luciferase activity,
indicating that construction of HCC-targeting amiRNAs by the precursor structure of miR-221 could
be widely used in HCC treatment [140]. We generated an oncolytic adenoviral vector, which can
specifically replicate with high copies in HCC cells, to express an artificially-designed interfering
lncRNA (lncRNAi) containing the complementary binding sequences to the seed sequences of the
12 oncogenic miRNAs, including miR-21, miR-221/222, miR-224, miR-17-5p/20a, miR-10b, miR-106b,

Genes 2017, 8, 21

6 of 15

miR-151-5p, miR-155, miR-181a/181b, miR-184, miR-1 and miR-501-5p. The lncRNAi expressed with
high level in HCC cells and competed with target genes of oncogenic miRNAs to bind to and consume
those oncogenic miRNAs, thereby achieving the target anti-tumor efficacy on HCC cell line xenograft
models and HCC patient-derived xenograft (PDX) models in nude mice [46].
4.3. Lung Cancer
Dysregulation of miRNAs contributes to lung carcinogenesis and progression. Fernandez et al.
found that the expression of miR-340 was inversely correlated with progression of non-small cell lung
cancer (NSCLC). Over-expression of miR-340 suppresses cell growth and induces apoptosis in NSCLC
cells [108]. miRNAs are always recognized as potential targets of cancer therapy, and effective delivery
strategies still need to be explored. Trang et al. and Ai et al. both reported that delivery of synthetic
mimics of suppressor miRNAs in complex with a novel neutral lipid emulsion by blood stream was
preferentially targeted to lung tumors and showed remarkable inhibition of tumors in a V-Ki-ras2
Kirsten rat sarcoma viral oncogene homolog (KRAS)-driven mouse models of lung cancer [141,142].
As we know, oncolytic virotherapy is a promising approach for the treatment of advanced NSCLC.
Since the expression of miR-145 is lower in NSCLC cells, Li et al. constructed a new oncolytic HSV-1
(AP27i145) carrying four copies of miR-145 target sites in the 30 -UTR of an HSV-1 essential viral
gene, infection cell protein 27 (ICP27). AP27i145 replication selectively inhibited the proliferation and
neoplastic capacity of NSCLC cells. Moreover, the combination of ionizing radiation and AP27i145
infection was obviously more effective in killing cancer cells than that of monotherapy [54].
4.4. Gastric Cancer
Gastric cancer remains one of the most common tumors and affects human health due to its
high morbidity and mortality. Studies have revealed that miRNAs are probably associated with
tumorigenesis of gastric cancer [143]. Lee et al. identified miR-130a and miR-495 as oncogenic
miRNA candidates, both of which are capable of targeting Runt-related transcription factor 3 (RUNX3)
and can decrease apoptosis and increase cell proliferation in SNU5 and SNU484 gastric cancer cells.
Furthermore, the synthetized antagomirs specific for miR-130a and miR-495 showed strong inhibitory
effect on cell growth and angiogenesis [109]. Down-regulation of miR-1 has been reported in gastric
cancer. Transfection of miR-1 mimics results in the suppression of cell proliferation and migration.
This study provides new insights into target therapy of gastric cancer [144]. In addition, an artificial
miRNA targeting liver-intestine cadherin (CDH17) via the lentivirus vector was applied to induce
a long-lasting knockdown of CDH17 expression in BGC823 cells, and the CDH17-miRNA-transfected
gastric cells showed a significant decrease in cell proliferation, cell motility, and migration in
comparison with the control cells [145].
4.5. Prostate Cancer
Prostate cancer is one of the leading causes among male cancer-related deaths. Recently, miRNAs
have demonstrated as critical post-transcriptional regulators of prostate cancer. Wang et al. reported
that transfection of miR-221/222 mimics in prostate cancer cells could increase the activity of cell
proliferation and inhibit the pro-apoptotic effect by suppressing caspase-10 [146]. Budd and his
colleagues found that inhibition of miR-22 or restoration of miR-125b impaired migratory and
invasive potential of prostate cancer cells in vitro [147]. Recent advances in efficient miRNA delivery
techniques using prostate cancer-targeted nanoparticles offer critical information for understanding
the functional role of miRNAs. Zhang et al. synthesized a polyarginine peptide (R11)-labeled non-toxic
disulfidebond polyethylenimine (SS-PEI) nanocarrier for delivery of miR-145 and demonstrated
that the systemic administration of R11-SSPEI/FAM-miR-145 complex dramatically inhibited tumor
growth and prolonged survival time in a mouse model of intraperitoneally implanting prostate cancer
xenografts, without any toxicity [55].

Genes 2017, 8, 21

7 of 15

4.6. Leukemia
MiRNAs can function either as oncogenes or tumor suppressor genes in leukemia, and open up
new opportunities for leukemia therapy. miR-126 was first validated to be a feasible therapeutic target
of acute myeloid leukemia (AML). The constructed targeting nanoparticles containing antagomiR-126
can deplete the quiescent cell subpopulation and then reduce the number of leukemia stem cells [148].
Jiang et al. developed a targeted nanoparticle system, FLT3 ligand (FLT3L)-conjugated G7 poly
nanosized dendriplex encapsulating miR-150, and demonstrated that the system selectively targets
FLT3-overexpressing AML cells and efficiently inhibits cell viability and induces apoptosis both in vitro
and in vivo [149]. Similarly, a non-viral system of transferrin (Tf)-conjugated anionic lipopolyplex
nanoparticles for miR-29b mimic transfection had many advantages, such as relatively high efficiency
of miRNA transfection and low cytotoxicity in AML cells [81]. Mignacca et al. reported that miRNA
sponges against miR-19 and miR-155 inhibited the functions of these miRNAs and enhanced the
induction of p53 and suppressor of cytokine signaling-1 (SOCS1) in human myeloma cells and mouse
leukemia cells, which indicated that the antagonizing miRNA activity could reactivate the activity of
cytokine-stimulated tumor suppressor pathways in leukemia cells [119].
5. Conclusions
As described above, there have been many new technological advances for utilizing miRNAs as
therapeutic tools for cancers. The better understanding of miRNA biogenesis and function undoubtedly
affects the research and development of miRNA-based therapies. Until now, several miRNAs
have been validated in preclinical tests and left for further clinical investigation. In 2013, the first
miRNA replacement therapy with MRX34—a liposome-formulated miR-34 mimic—entered human
clinical trials for patients with advanced or metastatic liver cancer by intravenous injection [150,151].
An antagonist of miR-122 was used for hepatitis C treatment and tested in phase II clinical trials [152].
Let-7 mimic was developed to treat a variety of solid carcinomas, such as lung cancer and prostate
cancer [91,92]. However, many questions regarding the miRNA-based cancer therapies remain to be
overcome, including the suboptimal delivery, low bioavailability, off-target effects or long term safety.
Potential employed methods may be the development of some novel miRNA-formulations including
nanoparticles, polymers and virus-based approaches. Overall, reprogramming miRNA networks in
cancer might constitute numerous reasonable and effective target strategies with a strong potential
and chance for success in the war against cancer.
Acknowledgments: This work was supported by the projects of National Natural Science Foundation of China
(81572863 to C.S., 81402565 to W.J., 81301830 to B.S.).
Conflicts of Interest: The authors declare no conflict of interest.

References
1.
2.

3.
4.
5.
6.

Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281–297. [CrossRef]
Lu, J.; Getz, G.; Miska, E.A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; Ebert, B.L.;
Mak, R.H.; Ferrando, A.A.; et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435,
834–838. [CrossRef] [PubMed]
Bohnsack, M.T.; Czaplinski, K.; Gorlich, D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that
mediates nuclear export of pre-miRNAs. RNA 2004, 10, 185–191. [CrossRef] [PubMed]
Hammond, S.M.; Bernstein, E.; Beach, D.; Hannon, G.J. An RNA directed nuclease mediates
post-transcriptional gene silencing in Drosophila cells. Nature 2000, 404, 293–296. [PubMed]
Lund, E.; Guttinger, S.; Calado, A.; Dahlberg, J.E.; Kutay, U. Nuclear export of microRNA precursors. Science
2004, 303, 95–98. [CrossRef] [PubMed]
Chitwood, D.H.; Timmermans, M.C. Small RNAs are on the move. Nature 2010, 467, 415–419. [CrossRef]
[PubMed]

Genes 2017, 8, 21

7.
8.
9.
10.
11.
12.

13.
14.
15.

16.

17.

18.

19.
20.

21.

22.

23.

24.

25.

26.

8 of 15

Ebert, M.S.; Sharp, P.A. MicroRNA sponges: Progress and possibilities. RNA 2010, 16, 2043–2050. [CrossRef]
[PubMed]
Budhu, A.; Ji, J.; Wang, X.W. The clinical potential of microRNAs. J. Hematol. Oncol. 2010, 3, 37. [CrossRef]
[PubMed]
Vasudevan, S.; Tong, Y.; Steitz, J.A. Switching from repression to activation: MicroRNAs can up-regulate
translation. Science 2007, 318, 1931–1934. [CrossRef] [PubMed]
Croce, C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009, 10,
704–714. [CrossRef] [PubMed]
Munker, R.; Calin, G.A. MicroRNA profiling in cancer. Clin. Sci (Lond.) 2011, 121, 141–158. [CrossRef]
[PubMed]
Volinia, S.; Calin, G.A.; Liu, C.G.; Ambs, S.; Cimmino, A.; Petrocca, F.; Visone, R.; Iorio, M.; Roldo, C.;
Ferracin, M.; et al. A microRNA expression signature of human solid tumors defines cancer gene targets.
Proc. Natl. Acad. Sci. USA 2006, 103, 2257–2261. [CrossRef]
Iorio, M.V.; Croce, C.M. MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol. Med. 2012, 4, 143–159. [CrossRef] [PubMed]
Kasinski, A.L.; Slack, F.J. Epigenetics and genetics. MicroRNAs en route to the clinic: Progress in validating
and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 2011, 11, 849–864. [CrossRef] [PubMed]
Calin, G.A.; Sevignani, C.; Dumitru, C.D.; Hyslop, T.; Noch, E.; Yendamuri, S.; Shimizu, M.; Rattan, S.;
Bullrich, F.; Negrini, M.; et al. Human microRNA genes are frequently located at fragile sites and genomic
regions involved in cancers. Proc. Natl. Acad. Sci. USA 2004, 101, 2999–3004. [CrossRef]
Saito, Y.; Liang, G.; Egger, G.; Friedman, J.M.; Chuang, J.C.; Coetzee, G.A.; Jones, P.A. Specific activation of
microRNAs-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human
cancer cells. Cancer Cell 2006, 9, 435–443. [CrossRef] [PubMed]
Lujambio, A.; Ropero, S.; Ballestar, E.; Fraga, M.F.; Cerrato, C.; Setién, F.; Casado, S.; Suarez-Gauthier, A.;
Sanchez-Cespedes, M.; Git, A.; et al. Genetic unmasking of an epigenetically silenced microRNA in human
cancer cells. Cancer Res. 2007, 67, 1424–1429. [CrossRef] [PubMed]
Hackanson, B.; Bennett, K.L.; Brena, R.M.; Jiang, J.; Claus, R.; Chen, S.S.; Blagitko-Dorfs, N.; Maharry, K.;
Whitman, S.P.; Schmittgen, T.D.; et al. Epigenetic modification of CCAAT/enhancer binding protein alpha
expression in acute myeloid leukemia. Cancer Res. 2008, 68, 3142–3151. [CrossRef] [PubMed]
Karagonlar, Z.F.; Korhan, P.; Atabey, N. Targeting c-Met in Cancer by MicroRNAs: Potential Therapeutic
Applications in Hepatocellular Carcinoma. Drug Dev. Res. 2015, 76, 357–367. [CrossRef] [PubMed]
Calin, G.A.; Dumitru, C.D.; Shimizu, M.; Bichi, R.; Zupo, S.; Noch, E.; Aldler, H.; Rattan, S.; Keating, M.;
Rai, K.; et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in
chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 2002, 99, 15524–15529. [CrossRef] [PubMed]
Ciafrè, S.A.; Galardi, S.; Mangiola, A.; Ferracin, M.; Liu, C.G.; Sabatino, G.; Negrini, M.; Maira, G.; Croce, C.M.;
Farace, M.G. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem. Biophys.
Res. Commun. 2005, 334, 1351–1358. [CrossRef] [PubMed]
Bloomston, M.; Frankel, W.L.; Petrocca, F.; Volinia, S.; Alder, H.; Hagan, J.P.; Liu, C.G.; Bhatt, D.; Taccioli, C.;
Croce, C.M. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas
and chronic pancreatitis. JAMA 2007, 297, 1901–1908. [CrossRef] [PubMed]
Iorio, M.V.; Ferracin, M.; Liu, C.G.; Veronese, A.; Spizzo, R.; Sabbioni, S.; Magri, E.; Pedriali, M.; Fabbri, M.;
Campiglio, M.; et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65,
7065–7070. [CrossRef] [PubMed]
Schetter, A.J.; Leung, S.Y.; Sohn, J.J.; Zanetti, K.A.; Bowman, E.D.; Yanaihara, N.; Yuen, S.T.; Chan, T.L.;
Kwong, D.L.; Au, G.K.; et al. MicroRNA expression profiles associated with prognosis and therapeutic
outcome in colon adenocarcinoma. JAMA 2008, 299, 425–436. [CrossRef] [PubMed]
Meng, F.; Henson, R.; Wehbe-Janek, H.; Ghoshal, K.; Jacob, S.T.; Patel, T. MicroRNA-21 Regulates Expression
of the PTEN Tumor Suppressor Gene in Human Hepatocellular Cancer. Gastroenterology 2007, 133, 647–658.
[CrossRef] [PubMed]
Frankel, L.B.; Christoffersen, N.R.; Jacobsen, A.; Lindow, M.; Krogh, A.; Lund, A.H. Programmed cell death 4
(PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J. Biol. Chem. 2008,
283, 1026–1033. [CrossRef] [PubMed]

Genes 2017, 8, 21

27.
28.

29.

30.
31.
32.
33.

34.

35.

36.
37.

38.
39.
40.
41.

42.

43.
44.
45.
46.

47.

9 of 15

Kumar, M.S.; Lu, J.; Mercer, K.L.; Golub, T.R.; Jacks, T. Impaired microRNA processing enhances cellular
transformation and tumorigenesis. Nat. Genet. 2007, 39, 673–677. [CrossRef] [PubMed]
Cimmino, A.; Calin, G.A.; Fabbri, M.; Iorio, M.V.; Ferracin, M.; Shimizu, M.; Wojcik, S.E.; Aqeilan, R.I.;
Zupo, S.; Dono, M.; et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. USA
2005, 102, 13944–13949. [CrossRef] [PubMed]
Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.;
Noteboom, J.; O’Briant, K.C.; Allen, A.; et al. Circulating microRNAs as stable blood-based markers for
cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105, 10513–10518. [CrossRef] [PubMed]
Ghai, V.; Wang, K. Recent progress toward the use of circulating microRNAs as clinical biomarkers.
Arch. Toxicol. 2016, 90, 2959–2978. [CrossRef] [PubMed]
Singh, R.; Ramasubramanian, B.; Kanji, S.; Chakraborty, A.R.; Haque, S.J.; Chakravarti, A. Circulating
microRNAs in cancer: Hope or hype? Cancer Lett. 2016, 381, 113–121. [CrossRef] [PubMed]
Chen, G.; Wang, J.; Cui, Q. Could circulating miRNAs contribute to cancer therapy? Trends Mol. Med. 2013,
19, 71–73. [CrossRef] [PubMed]
Bianchi, F.; Nicassio, F.; Marzi, M.; Belloni, E.; Dall’olio, V.; Bernard, L.; Pelosi, G.; Maisonneuve, P.;
Veronesi, G.; di Fiore, P.P. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk
individuals with early stage lung cancer. EMBO Mol. Med. 2011, 3, 495–503. [CrossRef] [PubMed]
Van Schooneveld, E.; Wouters, M.C.; Van der Auwera, I.; Peeters, D.J.; Wildiers, H.; Van Dam, P.A.; Vergote, I.;
Vermeulen, P.B.; Dirix, L.Y.; Van Laere, S.J. Expression profiling of cancerous and normal breast tissues
identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer
and healthy volunteers. Breast Cancer Res. 2012, 14, R34. [CrossRef] [PubMed]
Moltzahn, F.; Olshen, A.B.; Baehner, L.; Peek, A.; Fong, L.; Stöppler, H.; Simko, J.; Hilton, J.F.; Carroll, P.;
Blelloch, R. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures
in the sera of prostate cancer patients. Cancer Res. 2011, 71, 550–560. [CrossRef] [PubMed]
Maltby, S.; Plank, M.; Ptaschinski, C.; Mattes, J.; Foster, P.S. MicroRNA function in mast cell biology: Protocols
to characterize and modulate microRNA expression. Methods Mol. Biol. 2015, 1220, 287–304. [PubMed]
Kota, J.; Chivukula, R.R.; O’Donnell, K.A.; Wentzel, E.A.; Montgomery, C.L.; Hwang, H.W.; Chang, T.C.;
Vivekanandan, P.; Torbenson, M.; Clark, K.R.; et al. Therapeutic microRNA delivery suppresses
tumorigenesis in a murine liver cancer model. Cell 2009, 137, 1005–1017. [CrossRef] [PubMed]
Bader, A.G.; Brown, D.; Winkler, M. The promise of micro-RNA replacement therapy. Cancer Res. 2010, 70,
7027–7030. [CrossRef] [PubMed]
Tutar, L.; Tutar, E.; Tutar, Y. MicroRNAs and cancer; an over-view. Curr. Pharm. Biotechnol. 2014, 15, 430–437.
[CrossRef] [PubMed]
Ling, H.; Fabbri, M.; Calin, G.A. MicroRNAs and other noncoding RNAs as targets for anticancer drug
development. Nat. Rev. Drug Discov. 2013, 12, 847–865. [CrossRef] [PubMed]
Majid, S.; Dahiya, R. MicroRNA based therapeutic strategies for cancer: Emphasis on advances in renal cell
carcinoma. In MicroRNA Targeted Cancer Therapy; Sarkar, F.H., Ed.; Springer: New York, NY, USA, 2014;
pp. 175–188.
Elmen, J.; Lindow, M.; Schutz, S.; Lawrence, M.; Petri, A.; Obad, S.; Lindholm, M.; Hedtjärn, M.; Hansen, H.F.;
Berger, U.; et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008, 452, 896–899.
[CrossRef] [PubMed]
Esau, C.C. Inhibition of microRNA with antisense oligonucleotides. Methods 2008, 44, 55–60. [CrossRef]
[PubMed]
Krutzfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K.G.; Tuschl, T.; Manoharan, M.; Stoffel, M. Silencing of
microRNAs in vivowith ‘antagomirs’. Nature 2005, 438, 685–689. [CrossRef] [PubMed]
Czech, M.P. MicroRNAs as therapeutic targets. N. Engl. J. Med. 2006, 354, 1194–1195. [CrossRef] [PubMed]
Li, X.; Su, Y.; Sun, B.; Ji, W.; Peng, Z.; Xu, Y.; Wu, M.; Su, C. An artificially designed interfering lncRNA
expressed by oncolytic adenovirus competitively consumes oncomiRs to exert antitumor efficacy in
hepatocellular carcinoma. Mol. Cancer Ther. 2016, 15, 1436–1451. [CrossRef] [PubMed]
Su, Y.; Sun, B.; Lin, X.; Zhao, X.; Ji, W.; He, M.; Qian, H.; Song, X.; Yang, J.; Wang, J.; et al. Therapeutic strategy
with artificially-designed i-lncRNA targeting multiple oncogenic microRNAs exhibits effective antitumor
activity in diffuse large B-cell lymphoma. Oncotarget 2016, 7, 49143–49155. [CrossRef] [PubMed]

Genes 2017, 8, 21

48.
49.

50.

51.
52.

53.

54.

55.
56.

57.
58.
59.

60.

61.

62.

63.

64.

65.

66.

10 of 15

Ronald, J.A.; D’Souza, A.L.; Chuang, H.Y.; Gambhir, S.S. Artificial MicroRNAs as Novel Secreted Reporters
for Cell Monitoring in Living Subjects. PLoS ONE 2016, 11, e0159369. [CrossRef] [PubMed]
Liu, X.; Fang, H.; Chen, H.; Jiang, X.; Fang, D.; Wang, Y.; Zhu, D. An artificial miRNA against HPSE
suppresses melanoma invasion properties, correlating with a down-regulation of chemokines and MAPK
phosphorylation. PLoS ONE 2012, 7, e38659. [CrossRef] [PubMed]
Maczuga, P.; Koornneef, A.; Borel, F.; Petry, H.; van Deventer, S.; Ritsema, T.; Konstantinova, P. Optimization
and comparison of knockdown efficacy between polymerase II expressed shRNA and artificial miRNA
targeting luciferase and apolipoprotein B100. BMC Biotechnol. 2012, 12, 42. [CrossRef] [PubMed]
Boudreau, R.L.; Martins, I.; Davidson, B.L. Artificial microRNAs as siRNA shuttles: Improved safety as
compared to shRNAs in vitro and in vivo. Mol. Ther. 2009, 17, 169–175. [CrossRef] [PubMed]
McBride, J.L.; Boudreau, R.L.; Harper, S.Q.; Staber, P.D.; Monteys, A.M.; Martins, I.; Gilmore, B.L.;
Burstein, H.; Peluso, R.W.; Polisky, B.; et al. Artificial miRNAs mitigate shRNA-mediated toxicity in
the brain: Implications for the therapeutic development of RNAi. Proc. Natl. Acad. Sci. USA 2008, 105,
5868–5873. [CrossRef] [PubMed]
Boden, D.; Pusch, O.; Silbermann, R.; Lee, F.; Tucker, L.; Ramratnam, B. Enhanced gene silencing of HIV-1
specific siRNA using microRNA designed hairpins. Nucleic Acids Res. 2004, 32, 1154–1158. [CrossRef]
[PubMed]
Li, J.M.; Kao, K.C.; Li, L.F.; Yang, T.M.; Wu, C.P.; Horng, Y.M.; Jia, W.W.; Yang, C.T. MicroRNA-145 regulates
oncolytic herpes simplex virus-1 for selective killing of human non-small cell lung cancer cells. Virol. J.
2013, 10, 241. [CrossRef] [PubMed]
Zhang, T.; Xue, X.; He, D.; Hsieh, J.T. A prostate cancer-targeted polyarginine-disulfide linked PEI nanocarrier
for delivery of microRNA. Cancer Lett. 2015, 365, 156–165. [CrossRef] [PubMed]
Khan, S.; Ebeling, M.C.; Zaman, M.S.; Sikander, M.; Yallapu, M.M.; Chauhan, N.; Yacoubian, A.M.;
Behrman, S.W.; Zafar, N.; Kumar, D.; et al. MicroRNA-145 targets MUC13 and suppresses growth and
invasion of pancreatic cancer. Oncotarget 2014, 5, 7599–7609. [CrossRef] [PubMed]
Chen, Z.; Zeng, H.; Guo, Y.; Liu, P.; Pan, H.; Deng, A.; Hu, J. miRNA-145 inhibits non-small cell lung cancer
cell proliferation by targeting c-Myc. J. Exp. Clin. Cancer Res. 2010. [CrossRef] [PubMed]
Zheng, M.; Sun, X.; Li, Y.; Zuo, W. MicroRNA-145 inhibits growth and migration of breast cancer cells
through targeting oncoprotein ROCK1. Tumour Biol. 2016, 37, 8189–8196. [CrossRef] [PubMed]
Ding, W.; Tan, H.; Zhao, C.; Li, X.; Li, Z.; Jiang, C.; Zhang, Y.; Wang, L. miR-145 suppresses cell proliferation
and motility by inhibiting ROCK1 in hepatocellular carcinoma. Tumour Biol. 2016, 37, 6255–6260. [CrossRef]
[PubMed]
Tang, L.; Wei, D.; Yan, F. MicroRNA-145 functions as a tumor suppressor by targeting matrix
metalloproteinase 11 and RabGTPase family 27a in triple-negative breast cancer. Cancer Gene Ther. 2016, 23,
258–265. [CrossRef] [PubMed]
Zhao, H.; Kang, X.; Xia, X.; Wo, L.; Gu, X.; Hu, Y.; Xie, X.; Chang, H.; Lou, L.; Shen, X. miR-145 suppresses
breast cancer cell migration by targeting FSCN-1 and inhibiting epithelial-mesenchymal transition. Am. J.
Transl. Res. 2016, 8, 3106–3114. [PubMed]
Wang, W.; Ji, G.; Xiao, X.; Chen, X.; Qin, W.W.; Yang, F.; Li, Y.F.; Fan, L.N.; Xi, W.J.; Huo, Y.; et al. Epigenetically
regulated miR-145 suppresses colon cancer invasion and metastasis by targeting LASP1. Oncotarget 2016.
[CrossRef] [PubMed]
Mataki, H.; Seki, N.; Mizuno, K.; Nohata, N.; Kamikawaji, K.; Kumamoto, T.; Koshizuka, K.; Goto, Y.;
Inoue, H. Dual-strand tumor-suppressor microRNA-145 (miR-145–5p and miR-145–3p) coordinately targeted
MTDH in lung squamous cell carcinoma. Oncotarget 2016. [CrossRef] [PubMed]
Inamoto, T.; Taniguchi, K.; Takahara, K.; Iwatsuki, A.; Takai, T.; Komura, K.; Yoshikawa, Y.; Uchimoto, T.;
Saito, K.; Tanda, N.; et al. Intravesical administration of exogenous microRNA-145 as a therapy for mouse
orthotopic human bladder cancer xenograft. Oncotarget 2015, 6, 21628–21635. [CrossRef] [PubMed]
Sathyanarayanan, A.; Chandrasekaran, K.S.; Karunagaran, D. MicroRNA-145 modulates epithelial-mesenchymal
transition and suppresses proliferation, migration and invasion by targeting SIP1 in human cervical cancer
cells. Cell Oncol. 2016. [CrossRef] [PubMed]
Chang, S.; Gao, L.; Yang, Y.; Tong, D.; Guo, B.; Liu, L.; Li, Z.; Song, T.; Huang, C. miR-145 mediates the
antiproliferative and gene regulatory effects of vitamin D3 by directly targeting E2F3 in gastric cancer cells.
Oncotarget 2015, 6, 7675–7685. [CrossRef] [PubMed]

Genes 2017, 8, 21

67.

68.
69.

70.
71.
72.

73.
74.

75.

76.

77.

78.

79.

80.

81.

82.
83.

84.

11 of 15

Wang, C.; Tao, W.; Ni, S.; Chen, Q.; Zhao, Z.; Ma, L.; Fu, Y.; Jiao, Z. Tumor-suppressive microRNA-145
induces growth arrest by targeting SENP1 in human prostate cancer cells. Cancer Sci. 2015, 106, 375–382.
[CrossRef] [PubMed]
Zhang, Q.; Yan, W.; Bai, Y.; Xu, H.; Fu, C.; Zheng, W.; Zhu, Y.; Ma, J. Synthetic miR-145 mimic inhibits
multiple myeloma cell growth in vitro and in vivo. Oncol. Rep. 2015, 33, 448–456. [CrossRef] [PubMed]
Gougelet, A.; Sartor, C.; Bachelot, L.; Godard, C.; Marchiol, C.; Renault, G.; Tores, F.; Nitschke, P.; Cavard, C.;
Terris, B.; et al. Antitumour activity of an inhibitor of miR-34a in liver cancer with β-catenin-mutations. Gut
2016, 65, 1024–1034. [CrossRef] [PubMed]
Sun, F.; Fu, H.; Liu, Q.; Tie, Y.; Zhu, J.; Xing, R.; Sun, Z.; Zheng, X. Downregulation of CCND1 and CDK6 by
miR-34a induces cell cycle arrest. FEBS. Lett. 2008, 582, 1564–1568. [CrossRef] [PubMed]
Yamakuchi, M.; Ferlito, M.; Lowenstein, C.J. miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl.
Acad. Sci. USA 2008, 105, 13421–13426. [CrossRef] [PubMed]
Cole, K.A.; Attiyeh, E.F.; Mosse, Y.P.; Laquaglia, M.J.; Diskin, S.J.; Brodeu, G.M.; Maris, J.M. A functional
screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol. Cancer Res. 2008, 6,
735–742. [CrossRef] [PubMed]
Welch, C.; Chen, Y.; Stallings, R.L. MicroRNA-34a functions as a potential tumor suppressor by inducing
apoptosis in neuroblastoma cells. Oncogene 2007, 26, 5017–5022. [CrossRef] [PubMed]
Li, N.; Fu, H.; Tie, Y.; Hu, Z.; Kong, W.; Wu, Y.; Zheng, X. miR-34a inhibits migration and invasion by
down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett. 2009, 275, 44–53.
[CrossRef] [PubMed]
Li, Y.; Guessous, F.; Zhang, Y.; Dipierro, C.; Kefas, B.; Johnson, E.; Marcinkiewicz, L.; Jiang, J.; Yang, Y.;
Schmittgen, T.D.; et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes.
Cancer Res. 2009, 69, 7569–7576. [CrossRef] [PubMed]
Yamamura, S.; Saini, S.; Majid, S.; Hirata, H.; Ueno, K.; Deng, G.; Dahiya, R. MicroRNA-34a modulates c-Myc
transcriptional complexes to suppress malignancy in human prostate cancer cells. PLoS ONE 2012, 7, e29722.
[CrossRef] [PubMed]
Wu, J.; Wu, G.; Lv, L.; Ren, Y.F.; Zhang, X.J.; Xue, Y.F.; Li, G.; Lu, X.; Sun, Z.; Tang, K.F. MicroRNA-34a
inhibits migration and invasion of colon cancer cells via targeting to Fra-1. Carcinogenesis 2012, 33, 519–528.
[CrossRef] [PubMed]
Di Martino, M.T.; Campani, V.; Misso, G.; Gallo Cantafio, M.E.; Gullà, A.; Foresta, U.; Guzzi, P.H.;
Castellano, M.; Grimaldi, A.; Gigantino, V.; et al. In vivo activity of miR-34a mimics delivered by stable
nucleic acid lipid particles (SNALPs) against multiple myeloma. PLoS ONE 2014, 9, e90005. [CrossRef]
[PubMed]
Li, G.; Yao, L.; Zhang, J.; Li, X.; Dang, S.; Zeng, K.; Zhou, Y.; Gao, F. Tumor-suppressive microRNA-34a
inhibits breast cancer cell migration and invasion via targeting oncogenic TPD52. Tumour Biol. 2016, 37,
7481–7491. [CrossRef] [PubMed]
Adams, B.D.; Wali, V.B.; Cheng, C.J.; Inukai, S.; Booth, C.J.; Agarwal, S.; Rimm, D.L.; Győrffy, B.; Santarpia, L.;
Pusztai, L.; et al. miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer.
Cancer Res. 2016, 76, 927–939. [CrossRef] [PubMed]
Huang, X.; Schwind, S.; Yu, B.; Santhanam, R.; Wang, H.; Hoellerbauer, P.; Mims, A.; Klisovic, R.; Walker, A.R.;
Chan, K.K.; et al. Targeted Delivery of microRNA-29b by Transferrin Conjugated Anionic Lipopolyplex
Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia. Clin. Cancer Res. 2013, 19,
2355–2367. [CrossRef] [PubMed]
Mott, J.L.; Kobayashi, S.; Bronk, S.F.; Gores, G.J. Mir-29 regulates Mcl-1 protein expression and apoptosis.
Oncogene 2007, 26, 6133–6140. [CrossRef] [PubMed]
Xiong, Y.; Fang, J.H.; Yun, J.P.; Yang, J.; Zhang, Y.; Jia, W.H.; Zhuang, S.M. Effects of microRNA-29
on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010, 51, 836–845.
[CrossRef] [PubMed]
Fabbri, M.; Garzon, R.; Cimmino, A.; Liu, Z.; Zanesi, N.; Callegari, E.; Liu, S.; Alder, H.; Costinean, S.;
Fernandez-Cymering, C.; et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting
DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. USA 2007, 104, 15805–15810. [CrossRef] [PubMed]

Genes 2017, 8, 21

85.

12 of 15

Garzon, R.; Liu, S.; Fabbri, M.; Liu, Z.; Heaphy, C.E.; Callegari, E.; Schwind, S.; Pang, J.; Yu, J.;
Muthusamy, N.; et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene
reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood
2009, 113, 6411–6418. [CrossRef] [PubMed]
86. Kong, Y.; Zou, S.; Yang, F.; Xu, X.; Bu, W.; Jia, J.; Liu, Z. RUNX3-mediated up-regulation of miR-29b
suppresses the proliferation and migration of gastric cancer cells by targeting KDM2A. Cancer Lett. 2016, 381,
138–148. [CrossRef] [PubMed]
87. Langsch, S.; Baumgartner, U.; Haemmig, S.; Schlup, C.; Schäfer, S.C.; Berezowska, S.; Rieger, G.; Dorn, P.;
Tschan, M.P.; Vassella, E. miR-29b Mediates NF-κB Signaling in KRAS-Induced Non-Small Cell Lung Cancers.
Cancer Res. 2016, 76, 4160–4169. [CrossRef] [PubMed]
88. Zhu, K.; Liu, L.; Zhang, J.; Wang, Y.; Liang, H.; Fan, G.; Jiang, Z.; Zhang, C.Y.; Chen, X.; Zhou, G. MiR-29b
suppresses the proliferation and migration of osteosarcoma cells by targeting CDK6. Protein Cell 2016, 7,
434–444. [CrossRef] [PubMed]
89. Wang, H.; Guan, X.; Tu, Y.; Zheng, S.; Long, J.; Li, S.; Qi, C.; Xie, X.; Zhang, H.; Zhang, Y. MicroRNA-29b
attenuates non-small cell lung cancer metastasis by targeting matrix metalloproteinase 2 and PTEN. J. Exp.
Clin. Cancer Res. 2015, 34, 59. [CrossRef] [PubMed]
90. Chung, H.J.; Choi, Y.E.; Kim, E.S.; Han, Y.H.; Park, M.J.; Bae, I.H. miR-29b attenuates tumorigenicity and
stemness maintenance in human glioblastoma multiforme by directly targeting BCL2L2. Oncotarget 2015, 6,
18429–18444. [CrossRef] [PubMed]
91. Wu, X.Q.; Huang, C.; Liu, X.H.; Li, J. MicroRNAlet-7a: A novel therapeutic candidate inprostate cancer.
Asian J. Androl. 2014, 16, 327–328. [PubMed]
92. Yang, G.; Zhang, W.; Yu, C.; Ren, J.; An, Z. MicroRNAlet-7: Regulation, single nucleotide polymorphism,
and therapy in lung cancer. J. Cancer Res. Ther. 2015, 11, 1–6.
93. Trang, P.; Medina, P.P.; Wiggins, J.F.; Ruffino, L.; Kelnar, K.; Omotola, M.; Homer, R.; Brown, D.; Bader, A.G.;
Weidhaas, J.B.; et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010, 29, 1580–1587.
[CrossRef] [PubMed]
94. Akao, Y.; Nakagawa, Y.; Naoe, T. let-7 microRNA functions as a potential growth suppressor in human colon
cancer cells. Biol. Pharm. Bull. 2006, 29, 903–906. [CrossRef] [PubMed]
95. Sampson, V.B.; Rong, N.H.; Han, J.; Yang, Q.; Aris, V.; Soteropoulos, P.; Petrelli, N.J.; Dunn, S.P.; Krueger, L.J.
MicroRNA let-7a Down-regulates MYC and Reverts MYC-Induced Growth in Burkitt Lymphoma Cells.
Cancer Res. 2007, 67, 9762–9770. [CrossRef] [PubMed]
96. Lee, Y.S.; Dutta, A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 2007,
21, 1025–1030. [CrossRef] [PubMed]
97. Li, B.; Chen, P.; Chang, Y.; Qi, J.; Fu, H.; Guo, H. Let-7a inhibits tumor cell growth and metastasis by directly
targeting RTKN in human colon cancer. Biochem. Biophys. Res. Commun. 2016, 478, 739–745. [CrossRef]
[PubMed]
98. Zhang, Z.; Li, Y.; Huang, L.; Xiao, Q.; Chen, X.; Zhong, J.; Chen, Y.; Yang, D.; Han, Z.; Shu, Y.; et al. Let-7a
suppresses macrophage infiltrations and malignant phenotype of Ewing sarcoma via STAT3/NF-κB positive
regulatory circuit. Cancer Lett. 2016, 374, 192–201. [CrossRef] [PubMed]
99. Tang, R.; Yang, C.; Ma, X.; Wang, Y.; Luo, D.; Huang, C.; Xu, Z.; Liu, P.; Yang, L. MiR-let-7a inhibits cell
proliferation, migration, and invasion by down-regulating PKM2 in gastric cancer. Oncotarget 2016, 7,
5972–5984. [PubMed]
100. Liu, K.; Zhang, C.; Li, T.; Ding, Y.; Tu, T.; Zhou, F.; Qi, W.; Chen, H.; Sun, X. Let-7a inhibits growth and
migration of breast cancer cells by targeting HMGA1. Int. J. Oncol. 2015, 46, 2526–2534. [CrossRef] [PubMed]
101. Iwasaki, T.; Tanaka, K.; Kawano, M.; Itonaga, I.; Tsumura, H. Tumor-suppressive microRNA-let-7a inhibits
cell proliferation via targeting of E2F2 in osteosarcoma cells. Int. J. Oncol. 2015, 46, 1543–1550. [CrossRef]
[PubMed]
102. Yuan, J.; Ji, H.; Xiao, F.; Lin, Z.; Zhao, X.; Wang, Z.; Zhao, J.; Lu, J. MicroRNA-340 inhibits the proliferation
and invasion of hepatocellular carcinoma cells by targeting JAK1. Biochem. Biophys. Res. Commun. 2016.
[CrossRef] [PubMed]
103. Li, P.; Sun, Y.; Liu, Q. MicroRNA-340 Induces Apoptosis and Inhibits Metastasis of Ovarian Cancer Cells by
Inactivation of NF-κB1. Cell. Physiol. Biochem. 2016, 38, 1915–1927. [CrossRef] [PubMed]

Genes 2017, 8, 21

13 of 15

104. Mohammadi-Yeganeh, S.; Paryan, M.; Arefian, E.; Vasei, M.; Ghanbarian, H.; Mahdian, R.; Karimipoor, M.;
Soleimani, M. MicroRNA-340 inhibits the migration, invasion, and metastasis of breast cancer cells by
targeting Wnt pathway. Tumour Biol. 2016, 37, 8993–9000. [CrossRef] [PubMed]
105. Chen, C.P.; Sun, Z.L.; Lu, X.; Wu, W.X.; Guo, W.L.; Lu, J.J.; Han, C.; Huang, J.Q.; Fang, Y. miR-340 suppresses
cell migration and invasion by targeting MYO10 in breast cancer. Oncol. Rep. 2016, 35, 709–716. [CrossRef]
[PubMed]
106. Yu, W.; Zhang, G.; Lu, B.; Li, J.; Wu, Z.; Ma, H.; Wang, H.; Lian, R. miR-340 impedes the progression of
laryngeal squamous cell carcinoma by targeting EZH2. Gene 2016, 577, 193–201. [CrossRef] [PubMed]
107. Huang, D.; Qiu, S.; Ge, R.; He, L.; Li, M.; Li, Y.; Peng, Y. miR-340suppresses glioblastoma multiforme.
Oncotarget 2015, 6, 9257–9270. [CrossRef] [PubMed]
108. Fernandez, S.; Risolino, M.; Mandia, N.; Talotta, F.; Soini, Y.; Incoronato, M.; Condorelli, G.; Banfi, S.; Verde, P.
miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of
p27 in non-small cell lung cancer. Oncogene 2015, 34, 3240–3250. [CrossRef] [PubMed]
109. Lee, S.H.; Jung, Y.D.; Choi, Y.S.; Lee, Y.M. Targeting of RUNX3 by miR-130a and miR-495 cooperatively
increases cell proliferation and tumor angiogenesis in gastric cancer cells. Oncotarget 2015, 6, 33269–33278.
[PubMed]
110. Zhang, B.; Yuan, F.; Liu, J.; Li, Y.; Zhou, F.; Liu, X.; Hao, Z.; Li, Q.; Zheng, Y.; Wang, W. Hsa-miR-495 acts as
a tumor suppressor gene in glioma via the negative regulation of MYB. Mol. Med. Rep. 2016, 14, 977–982.
[CrossRef] [PubMed]
111. Li, J.Z.; Wang, Z.L.; Xu, W.H.; Li, Q.; Gao, L.; Wang, Z.M. MicroRNA-495 Regulates Migration and Invasion in
Prostate Cancer Cells Via Targeting Akt and mTOR Signaling. Cancer Investig. 2016, 34, 181–188. [CrossRef]
[PubMed]
112. Xu, Y.Y.; Tian, J.; Hao, Q.; Yin, L.R. MicroRNA-495 downregulates FOXC1 expression to suppress cell growth
and migration in endometrial cancer. Tumour Biol. 2016, 37, 239–251. [CrossRef] [PubMed]
113. Wang, L.; Liu, J.L.; Yu, L.; Liu, X.X.; Wu, H.M.; Lei, F.Y.; Wu, S.; Wang, X. Downregulated miR-495 Inhibits
the G1-S Phase Transition by Targeting Bmi-1 in Breast Cancer. Medicine 2015, 94, e718. [CrossRef] [PubMed]
114. Jiang, X.; Huang, H.; Li, Z.; He, C.; Li, Y.; Chen, P.; Gurbuxani, S.; Arnovitz, S.; Hong, G.M.; Price, C.; et al.
miR-495is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia. Proc. Natl. Acad.
Sci. USA 2012, 109, 19397–19402. [CrossRef] [PubMed]
115. Chu, H.; Chen, X.; Wang, H.; Du, Y.; Wang, Y.; Zang, W.; Li, P.; Li, J.; Chang, J.; Zhao, G.; et al. miR-495
regulates proliferation and migration in NSCLC by targeting MTA3. Tumour Biol. 2014, 35, 3487–3494.
[CrossRef] [PubMed]
116. Cao, M.; Nie, W.; Li, J.; Zhang, Y.; Yan, X.; Guan, X.; Chen, X.; Zen, K.; Zhang, C.Y.; Jiang, X.; et al.
MicroRNA-495 induces breast cancer cell migration by targeting JAM-A. Protein Cell 2014, 5, 862–872.
[CrossRef] [PubMed]
117. Li, Z.; Cao, Y.; Jie, Z.; Liu, Y.; Li, Y.; Li, J.; Zhu, G.; Liu, Z.; Tu, Y.; Peng, G.; et al. miR-495 and miR-551a inhibit
the migration and invasion of human gastric cancer cells by directly interacting with PRL-3. Cancer Lett.
2012, 323, 41–47. [CrossRef] [PubMed]
118. Zheng, S.R.; Guo, G.L.; Zhai, Q.; Zou, Z.Y.; Zhang, W. Effects of miR-155 antisense oligonucleotide on breast
carcinoma cell line MDA-MB-157 and implanted tumors. Asian Pac. J. Cancer Prev. 2013, 14, 2361–2366.
[CrossRef] [PubMed]
119. Mignacca, L.; Saint-Germain, E.; Benoit, A.; Bourdeau, V.; Moro, A.; Ferbeyre, G. Sponges against miR-19
and miR-155 reactivate the p53-Socs1 axis in hematopoietic cancers. Cytokine 2016, 82, 80–86. [CrossRef]
[PubMed]
120. O’Connell, R.M.; Rao, D.S.; Chaudhuri, A.A.; Boldin, M.P.; Taganov, K.D.; Nicoll, J.; Paquette, R.L.;
Baltimore, D. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative
disorder. J. Exp. Med. 2008, 205, 585–594. [CrossRef] [PubMed]
121. O’Connell, R.M.; Chaudhuri, A.A.; Rao, D.S.; Baltimore, D. Inositol phosphatase SHIP1 is a primary target of
miR-155. Proc. Natl Acad. Sci. USA 2009, 106, 7113–7118. [CrossRef] [PubMed]
122. Costinean, S.; Sandhu, S.K.; Pedersen, I.M.; Tili, E.; Trotta, R.; Perrotti, D.; Ciarlariello, D.; Neviani, P.;
Harb, J.; Kauffman, L.R.; et al. Src homology 2 domain-containing inositol-5-phosphatase and CCAAT
enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood
2009, 114, 1374–1382. [CrossRef] [PubMed]

Genes 2017, 8, 21

14 of 15

123. Kluiver, J.; Poppema, S.; de Jong, D.; Blokzijl, T.; Harms, G.; Jacobs, S.; Kroesen, B.J.; van den Berg, A. BIC
and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas.
J. Pathol. 2005, 207, 243–249. [CrossRef] [PubMed]
124. Xue, X.; Liu, Y.; Wang, Y.; Meng, M.; Wang, K.; Zang, X.; Zhao, S.; Sun, X.; Cui, L.; Pan, L.; et al. miR-21 and
miR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN.
Oncotarget 2016. [CrossRef] [PubMed]
125. Tang, B.; Lei, B.; Qi, G.; Liang, X.; Tang, F.; Yuan, S.; Wang, Z.; Yu, S.; He, S. microRNA-155–3p promotes
hepatocellular carcinoma formation by suppressing FBXW7 expression. Exp. Clin. Cancer Res. 2016.
[CrossRef] [PubMed]
126. Jiang, Y.X.; Du, Z.M.; Jiao, L.; Shao, Q.; Fu, S.; Shao, J.Y.; Zhu, X.F.; Ernberg, I.; Li, Y.H. Inhibition of miR-155
suppresses cell migration in nasopharyngeal carcinoma through targeting ZDHHC2. Int. J. Clin. Exp. Med.
2015, 8, 8472–8484. [PubMed]
127. Chan, J.A.; Krichevsky, A.M.; Kosik, K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma
cells. Cancer Res. 2005, 65, 6029–6033. [CrossRef] [PubMed]
128. Zhu, S.; Si, M.-L.; Wu, H.; Mo, Y.Y. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1).
J. Biol. Chem. 2007, 282, 14328–14336. [CrossRef] [PubMed]
129. Go, H.; Jang, J.Y.; Kim, P.J.; Kim, Y.G.; Nam, S.J.; Paik, J.H.; Kim, T.M.; Heo, D.S.; Kim, C.W.; Jeon, Y.K.
MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse
large B-cell lymphoma. Oncotarget 2015, 6, 15035–15049. [CrossRef] [PubMed]
130. Najafi, Z.; Sharifi, M.; Javadi, G. Degradation of miR-21 induces apoptosis and inhibits cell proliferation in
human hepatocellular carcinoma. Cancer Gene Ther. 2015, 22, 530–535. [CrossRef] [PubMed]
131. Liu, Z.L.; Wang, H.; Liu, J.; Wang, Z.X. MicroRNA-21 (miR-21) expression promotes growth, metastasis, and
chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol. Cell. Biochem. 2013,
372, 35–45. [CrossRef] [PubMed]
132. Leone, E.; Morelli, E.; di Martino, M.T.; Amodio, N.; Foresta, U.; Gullà, A.; Rossi, M.; Neri, A.; Giordano, A.;
Munshi, N.C.; et al. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.
Clin. Cancer Res. 2013, 19, 2096–2106. [CrossRef] [PubMed]
133. Wang, P.; Zou, F.; Zhang, X.; Li, H.; Dulak, A.; Tomko, R.J., Jr.; Lazo, J.S.; Wang, Z.; Zhang, L.; Yu, J.
microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res. 2009,
69, 8157–8165. [CrossRef] [PubMed]
134. Romero-Cordoba, S.; Rodriguez-Cuevas, S.; Rebollar-Vega, R.; Quintanar-Jurado, V.; Maffuz-Aziz, A.;
Jimenez-Sanchez, G.; Bautista-Piña, V.; Arellano-Llamas, R.; Hidalgo-Miranda, A. Identification and pathway
analysis of microRNAs with no previous involvement in breast cancer. PLoS ONE 2012, 7, e31904. [CrossRef]
[PubMed]
135. Jiang, L.; Yu, L.; Zhang, X.; Lei, F.; Wang, L.; Liu, X.; Wu, S.; Zhu, J.; Wu, G.; Cao, L.; et al. MiR-892b Silencing
Activates NF-κB and Promotes Aggressiveness in Breast Cancer. Cancer Res. 2016, 76, 1101–1111. [CrossRef]
[PubMed]
136. Tseng, C.W.; Huang, H.C.; Shih, A.C.; Chang, Y.Y.; Hsu, C.C.; Chang, J.Y.; Li, W.H.; Juan, H.F. Revealing the
anti-tumor effect of artificial miRNA p-27–5p on human breast carcinoma cell line T-47D. Int. J. Mol. Sci.
2012, 13, 6352–6369. [CrossRef] [PubMed]
137. Liang, Z.; Wu, H.; Reddy, S.; Zhu, A.; Wang, S.; Blevins, D.; Yoon, Y.; Zhang, Y.; Shim, H. Blockade of invasion
and metastasis of breast cancer cells via targeting CXCR4 with an artificial microRNA. Biochem. Biophys.
Res. Commun. 2007, 363, 542–546. [CrossRef] [PubMed]
138. Zhou, X.; Zhang, C.Z.; Lu, S.X.; Chen, G.G.; Li, L.Z.; Liu, L.L.; Yi, C.; Fu, J.; Hu, W.; Wen, J.M.; et al. miR-625
suppresses tumour migration and invasion by targeting IGF2BP1 in hepatocellular carcinoma. Oncogene
2015, 34, 965–977. [CrossRef] [PubMed]
139. Zhang, W.; Peng, F.; Zhou, T.; Huang, Y.; Zhang, L.; Ye, P.; Lu, M.; Yang, G.; Gai, Y.; Yang, T.; et al. Targeted
delivery of chemically modified anti-miR-221 to hepatocellular carcinoma with negatively charged liposomes.
Int. J. Nanomed. 2015, 29, 4825–4836.
140. Huang, X.; Jia, Z. Construction of HCC-targeting artificial miRNAs using natural miRNA precursors.
Exp. Ther. Med. 2013, 6, 209–215. [PubMed]

Genes 2017, 8, 21

15 of 15

141. Trang, P.; Wiggins, J.F.; Daige, C.L.; Cho, C.; Omotola, M.; Brown, D.; Weidhaas, J.B.; Bader, A.G.; Slack, F.J.
Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung
tumors in mice. Mol. Ther. 2011, 19, 1116–1122. [CrossRef] [PubMed]
142. Ai, C.; Jiang, R.; Fu, L.; Chen, Y. MicroRNA-495 mimics delivery inhibits lung tumor progression. Tumour Biol.
2015, 36, 729–735. [CrossRef] [PubMed]
143. Zhang, M.; Du, X. Noncoding RNAs in gastric cancer: Research progress and prospects. World J. Gastroenterol.
2016, 22, 6610–6618. [CrossRef] [PubMed]
144. Han, C.; Zhou, Y.; An, Q.; Li, F.; Li, D.; Zhang, X.; Yu, Z.; Zheng, L.; Duan, Z.; Kan, Q. MicroRNA-1 (miR-1)
inhibits gastric cancer cell proliferation and migration by targeting MET. Tumour Biol. 2015, 36, 6715–6723.
[CrossRef] [PubMed]
145. Zhang, J.; Liu, Q.S.; Dong, W.G. Blockade of proliferation and migration of gastric cancer via targeting
CDH17 with an artificial microRNA. Med. Oncol. 2011, 28, 494–501. [CrossRef] [PubMed]
146. Wang, L.; Liu, C.; Li, C.; Xue, J.; Zhao, S.; Zhan, P.; Lin, Y.; Zhang, P.; Jiang, A.; Chen, W. Effects of
microRNA-221/222 on cell proliferation and apoptosis in prostate cancer cells. Gene 2015, 572, 252–258.
[CrossRef] [PubMed]
147. Budd, W.T.; Seashols-Williams, S.J.; Clark, G.C.; Weaver, D.; Calvert, V.; Petricoin, E.; Dragoescu, E.A.;
O’Hanlon, K.; Zehner, Z.E. Dual Action of miR-125b As a Tumor Suppressor and OncomiR-22 Promotes
Prostate Cancer Tumorigenesis. PLoS ONE 2015, 10, e0142373. [CrossRef] [PubMed]
148. Dorrance, A.M.; Neviani, P.; Ferenchak, G.J.; Huang, X.; Nicolet, D.; Maharry, K.S.; Ozer, H.G.;
Hoellarbauer, P.; Khalife, J.; Hill, E.B.; et al. Targeting leukemia stem cells in vivo with antagomiR-126
nanoparticles in acute myeloid leukemia. Leukemia 2015, 29, 2143–2153. [CrossRef] [PubMed]
149. Jiang, X.; Bugno, J.; Hu, C.; Yang, Y.; Herold, T.; Qi, J.; Chen, P.; Gurbuxani, S.; Arnovitz, S.; Strong, J.; et al.
Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles. Cancer Res.
2016, 76, 4470–4480. [CrossRef] [PubMed]
150. MiRNA Therapeutics. Press Release: MiRNA Therapeutics is First to Advance MicroRNA into the Clinic for
Cancer. Available online: www.mirnarx.com (accessed on 25 August 2014).
151. Beg, M.S.; Brenner, A.J.; Sachdev, J.; Borad, M.; Kang, Y.K.; Stoudemire, J.; Smith, S.; Bader, A.G.; Kim, S.;
Hong, D.S. Phase I study of MRX34, a liposomalmiR-34a mimic, administered twice weekly in patients with
advanced solid tumors. Investig. New Drugs 2016. [CrossRef] [PubMed]
152. Janssen, H.L.; Reesink, H.W.; Lawitz, E.J.; Zeuzem, S.; Rodriguez-Torres, M.; Patel, K.; van derMeer, A.J.;
Patick, A.K.; Chen, A.; Zhou, Y.; et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med.
2013, 368, 1685–1694. [CrossRef] [PubMed]
© 2017 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).

